文献速递妇科

卵巢癌细胞系在PARP抑制剂治疗中的基因组与表达动态揭示获得性耐药机制

Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
PubMed 文献 · Gynecol Oncol · 2022-10-19

研究通过奥拉帕利暴露建立三株PARP抑制剂(PARPi)耐药细胞系,结合全外显子测序与RNA测序分析原发与获得性耐药的差异机制。长期PARPi治疗诱导新发单核苷酸变异(SNV)积累,A2780耐药株中检测到PARP1完全移码缺失;EP300组蛋白乙酰转移酶活性降低通过激活上皮-间质转化(EMT)在体外导致耐药表型,并与卵巢癌患者PARPi耐药相关。

要点

  • 原发PARPi耐药不能完全由BRCA1/2或同源重组缺陷相关基因突变解释。
  • 长期PARPi治疗诱导新发SNV积累,A2780耐药株中检测到PARP1完全移码缺失。
  • EP300组蛋白乙酰转移酶活性降低通过激活EMT在体外导致耐药表型,并与患者PARPi耐药相关。

核心结论

  • 长期PARPi治疗导致与获得性耐药相关的基因组和转录组进化改变,其中EP300活性降低部分贡献耐药表型。

研究设计与样本

  • 研究建立三株奥拉帕利暴露后的PARPi耐药细胞系,采用CCK-8、克隆形成、Transwell、划痕愈合、细胞周期、RT-qPCR和蛋白质印迹检测耐药细胞功能表型。
  • 采用全外显子测序和RNA测序识别改变基因,通过稳定敲低和过表达研究EP300(E-钙黏蛋白和上皮-间质转化(EMT)的上游调控因子)的作用,并用免疫组化在临床卵巢癌样本中验证。

主要发现

  • 公共数据集整合的EOC细胞PARPi敏感性谱提示原发PARPi耐药不能完全由BRCA1/2或同源重组缺陷相关基因突变解释。
  • 基因组和转录组分析揭示原发耐药与获得性耐药机制不同。
  • 长期PARPi治疗诱导新发单核苷酸变异(SNV)积累,A2780耐药株中检测到PARP1完全移码缺失。
  • EP300组蛋白乙酰转移酶活性降低通过激活EMT在体外导致耐药表型,并与EOC患者PARPi耐药相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with epithelial ovarian cancer (EOC) can benefit from poly- (ADP ribose) polymerase inhibitors (PARPi) therapy. However, PARPi resistance has become a challenge in clinical practice, and its mechanism requires further exploration. METHODS: We established three PARPi-resistant cell strains following olaparib exposure. CCK-8, clonogenic survival, transwell, wound healing, cell cycle, RT-qPCR and western blot assays were performed to explore the functional phenotype of the resistant cells. Whole-exome sequencing and RNA-sequencing were performed to identify the altered genes. Stable knockdown and overexpression were used to investigate the role of EP300, an upstream regulator of E-cadherin and epithelial-mesenchymal transition (EMT), in cell lines. We further validated the finding in clinical ovarian cancer samples by immunohistochemistry. RESULTS: We combined public datasets to obtain an integrated PARPi sensitivity profile in EOC cells, which indicated that primary PARPi resistance could not be fully explained by mutations in BRCA1/2 or homologous recombination deficiency related genes. Genomic and transcriptome analyses revealed distinct mechanisms between primary and acquired resistance. Long-term PARPi treatment induced accumulation of de novo single nucleotide variants (SNV), and the complete frame-shift deletion of PARP1 was detected in the A2780 resistant strain. Additionally, the depressed histone acetyltransferase of EP300 could cause resistant phenotype through activated EMT process in vitro, and associated with PARPi-resistance in EOC patients. CONCLUSION: Long-term PARPi treatment led to evolutionary genomic and transcriptional alterations that were associated with acquired resistance, among which depressed EP300 partly contributed to the resistant phenotype.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cheng A, Rao Q, Liu Y, et al. Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance. Gynecol Oncol. 2022. PMID: 36270832. doi:10.1016/j.ygyno.2022.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。